Correlation of Genomic Variation in Enzymes Responsible for Metabolism of Capecitabine With Drug Metabolism
Status:
Withdrawn
Trial end date:
2021-01-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find out how gene expression (as well as how
often this expression occurs) in patients with breast cancer affects how Xeloda®
(capecitabine) is cleared (passed through the urine) from the body. The safety of
capecitabine will also be studied.